Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 43.27 Billion KRW | 16.84% |
| 2022 | 37.03 Billion KRW | 26.34% |
| 2021 | 29.31 Billion KRW | 11.06% |
| 2020 | 26.39 Billion KRW | -4.81% |
| 2019 | 27.72 Billion KRW | -34.99% |
| 2018 | 42.65 Billion KRW | 36.6% |
| 2017 | 31.22 Billion KRW | -22.07% |
| 2016 | 40.06 Billion KRW | 1.47% |
| 2015 | 39.48 Billion KRW | -1.43% |
| 2014 | 40.05 Billion KRW | 3.27% |
| 2013 | 38.78 Billion KRW | 2.09% |
| 2012 | 37.99 Billion KRW | 8.77% |
| 2011 | 34.93 Billion KRW | 6.73% |
| 2010 | 32.72 Billion KRW | 4.97% |
| 2009 | 31.17 Billion KRW | 16.53% |
| 2008 | 26.75 Billion KRW | -14.74% |
| 2007 | 31.38 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 52.67 Billion KRW | 12.3% |
| 2024 Q1 | 46.91 Billion KRW | 8.41% |
| 2023 Q4 | 43.27 Billion KRW | -4.49% |
| 2023 Q3 | 45.3 Billion KRW | 15.69% |
| 2023 FY | 43.27 Billion KRW | 16.84% |
| 2023 Q2 | 39.16 Billion KRW | 5.61% |
| 2023 Q1 | 37.08 Billion KRW | 0.12% |
| 2022 Q2 | 33.48 Billion KRW | 1.72% |
| 2022 Q1 | 32.91 Billion KRW | 12.29% |
| 2022 FY | 37.03 Billion KRW | 26.34% |
| 2022 Q4 | 37.03 Billion KRW | 5.49% |
| 2022 Q3 | 35.1 Billion KRW | 4.86% |
| 2021 Q1 | 23.84 Billion KRW | -9.66% |
| 2021 Q3 | 30.79 Billion KRW | 26.39% |
| 2021 Q4 | 29.31 Billion KRW | -4.79% |
| 2021 FY | 29.31 Billion KRW | 11.06% |
| 2021 Q2 | 24.36 Billion KRW | 2.16% |
| 2020 Q1 | 26.28 Billion KRW | -5.2% |
| 2020 FY | 26.39 Billion KRW | -4.81% |
| 2020 Q2 | 27.99 Billion KRW | 6.52% |
| 2020 Q4 | 26.39 Billion KRW | -7.32% |
| 2020 Q3 | 28.47 Billion KRW | 1.71% |
| 2019 Q2 | 27.71 Billion KRW | -35.97% |
| 2019 Q3 | 27.49 Billion KRW | -0.81% |
| 2019 Q4 | 27.72 Billion KRW | 0.86% |
| 2019 FY | 27.72 Billion KRW | -34.99% |
| 2019 Q1 | 43.28 Billion KRW | 1.49% |
| 2018 Q4 | 42.65 Billion KRW | -1.08% |
| 2018 Q1 | 31.27 Billion KRW | 0.16% |
| 2018 FY | 42.65 Billion KRW | 36.6% |
| 2018 Q2 | 42.09 Billion KRW | 34.62% |
| 2018 Q3 | 43.11 Billion KRW | 2.42% |
| 2017 Q2 | 38.44 Billion KRW | 1.54% |
| 2017 Q4 | 31.22 Billion KRW | -15.83% |
| 2017 FY | 31.22 Billion KRW | -22.07% |
| 2017 Q3 | 37.09 Billion KRW | -3.51% |
| 2017 Q1 | 37.86 Billion KRW | -5.51% |
| 2016 Q3 | 39.52 Billion KRW | 0.64% |
| 2016 Q4 | 40.06 Billion KRW | 1.36% |
| 2016 Q1 | 39.13 Billion KRW | -0.88% |
| 2016 FY | 40.06 Billion KRW | 1.47% |
| 2016 Q2 | 39.27 Billion KRW | 0.35% |
| 2015 Q1 | 41.17 Billion KRW | 2.8% |
| 2015 Q4 | 39.48 Billion KRW | -1.75% |
| 2015 Q3 | 40.18 Billion KRW | -1.07% |
| 2015 FY | 39.48 Billion KRW | -1.43% |
| 2015 Q2 | 40.62 Billion KRW | -1.34% |
| 2014 Q2 | 38.07 Billion KRW | 0.08% |
| 2014 FY | 40.05 Billion KRW | 3.27% |
| 2014 Q4 | 40.05 Billion KRW | -0.2% |
| 2014 Q3 | 40.13 Billion KRW | 5.4% |
| 2014 Q1 | 38.04 Billion KRW | -1.91% |
| 2013 Q3 | 36.32 Billion KRW | -2.54% |
| 2013 Q4 | 38.78 Billion KRW | 6.79% |
| 2013 FY | 38.78 Billion KRW | 2.09% |
| 2013 Q2 | 37.26 Billion KRW | 3.53% |
| 2013 Q1 | 35.99 Billion KRW | -5.26% |
| 2012 Q1 | 36.87 Billion KRW | 0.0% |
| 2012 FY | 37.99 Billion KRW | 8.77% |
| 2012 Q4 | 37.99 Billion KRW | -1.44% |
| 2012 Q3 | 38.54 Billion KRW | -0.58% |
| 2012 Q2 | 38.77 Billion KRW | 5.16% |
| 2011 FY | 34.93 Billion KRW | 6.73% |
| 2011 Q3 | 35.28 Billion KRW | 10.24% |
| 2011 Q2 | 32 Billion KRW | -5.93% |
| 2011 Q1 | 34.02 Billion KRW | 3.95% |
| 2010 Q1 | 35.53 Billion KRW | 13.97% |
| 2010 FY | 32.72 Billion KRW | 4.97% |
| 2010 Q4 | 32.72 Billion KRW | -19.66% |
| 2010 Q3 | 40.73 Billion KRW | 5.6% |
| 2010 Q2 | 38.57 Billion KRW | 8.56% |
| 2009 Q4 | 31.17 Billion KRW | 12.99% |
| 2009 FY | 31.17 Billion KRW | 16.53% |
| 2009 Q2 | 30.66 Billion KRW | 12.57% |
| 2009 Q1 | 27.24 Billion KRW | 1.82% |
| 2009 Q3 | 27.59 Billion KRW | -10.03% |
| 2008 Q1 | 26.69 Billion KRW | -14.94% |
| 2008 Q3 | 24.96 Billion KRW | -0.45% |
| 2008 FY | 26.75 Billion KRW | -14.74% |
| 2008 Q4 | 26.75 Billion KRW | 7.16% |
| 2008 Q2 | 25.08 Billion KRW | -6.04% |
| 2007 Q1 | 31.17 Billion KRW | 0.0% |
| 2007 Q3 | 30.99 Billion KRW | -0.28% |
| 2007 Q2 | 31.08 Billion KRW | -0.28% |
| 2007 FY | 31.38 Billion KRW | 0.0% |
| 2007 Q4 | 31.38 Billion KRW | 1.23% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -9.81% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 93.746% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 88.674% |
| HANDOK Inc. | 300.01 Billion KRW | 85.576% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -41.128% |
| Yuhan Corporation | 230.07 Billion KRW | 81.192% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 89.36% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -7166.809% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 92.446% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -3253.105% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 49.186% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 52.175% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -63.09% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -9.81% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -18072.234% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 80.772% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 76.092% |
| JW Holdings Corporation | 554.58 Billion KRW | 92.197% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 80.136% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 80.309% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 74.587% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 6.237% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -10.376% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 75.396% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 49.07% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -9.81% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 81.636% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 90.787% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 74.587% |
| Yuhan Corporation | 230.07 Billion KRW | 81.192% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 74.991% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 35.3% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 90.751% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 74.587% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 63.525% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -7.273% |
| CKD Bio Corp. | 146.92 Billion KRW | 70.548% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 70.371% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 10.325% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -6746.688% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 6.237% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 90.754% |
| Boryung Corporation | 204.21 Billion KRW | 78.81% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 45.491% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 49.186% |
| JW Lifescience Corporation | 46.31 Billion KRW | 6.564% |